A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for gemcitabine

Gemcitabine is widely used in the treatment of various cancers. This study aims to evaluate gemcitabine-associated adverse events (AEs) using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.